Curasight A/S (NGM:CURAS)

Sweden flag Sweden · Delayed Price · Currency is SEK · Price in DKK
2.700
0.00 (0.00%)
At close: Jul 22, 2025
Market Cap198.17M
Revenue (ttm)n/a
Net Income (ttm)-49.52M
Shares Out45.87M
EPS (ttm)-2.32
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume63,814
Average Volume139,118
Open2.710
Previous Close2.700
Day's Range2.580 - 2.710
52-Week Range1.800 - 13.400
Beta0.03
RSI60.78
Earnings DateAug 28, 2025

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, which are in the pre-clinical stage to treat glioblastoma (brain cancer), as well as have completed the pre-clinical stage for the treatment of non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company also develops uTRACE diagnostic solutions, which are in Phase II to treat prostate cancer, as well as have completed Phase II for the treatment of glioblastoma (b... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2013
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol CURAS
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.